Key facts
- It has raised $14.0M; the latest was Early Stage VC ($14.0M) in Sep 2025.
- Notable investors include Northern Light Venture Capital, Dongxing Capital, Future Innovation Fund, Tahoe Venture.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Hongxing Xianghe
- ·The full record, as it builds
Funding rounds
No funding rounds for Hongxing Xianghe are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hongxing Xianghe
Developer of precision medical devices designed to improve clinical care and diagnostic reliability. The company offers advanced manufacturing capabilities, strict quality control protocols, and scalable production infrastructure, enabling healthcare institutions and distributors to access dependable equipment and accelerate operational performance.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- hidiamondbio.com/
- Ownership
- Privately Held (backing)
Hongxing Xianghe doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hongxing Xianghe shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hongxing Xianghe in its N-PORT filings yet. We sweep new filings monthly.